Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 38,075 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

38,075 Papers indexed
963 Papers AI scored
38,075 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

38075 results
B
H3K27M-altered diffuse midline glioma: Experience and outcomes from a low-middle income country setting in the contemporary era.
PMID 42180673 Published: 2026-05-04 Ingested: 2026-08-02 12:06 AM Neuro-oncology advances
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Clinicopathological characteristics and prognosis of central nervous system solitary fibrous tumor: An analysis of 271 cases.
PMID 42155214 Published: 2026-05-12 Ingested: 2026-08-02 12:06 AM Pathology, research and practice
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 55.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Assessing the sodium-iodide symporter (NIS) in pediatric differentiated thyroid carcinoma.
PMID 42048109 Published: 2026-05-08 Ingested: 2026-08-02 12:06 AM European thyroid journal
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 40.0; sample size: 50.0; recency: 100.0; abstract quality: 85.0.

B
Experiences from inborn errors of immunity registry of India: A preliminary report.
PMID 41949132 Published: 2026-02-01 Ingested: 2026-08-02 12:06 AM The Indian journal of medical research
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 35.0; sample size: 100.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 10.0; sample size: 70.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Base 70.5
Rank 70.5
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 15.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 586 of 3173
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic